Apellis Pharmaceuticals Inc ROCE
Was ist das ROCE von Apellis Pharmaceuticals Inc?
ROCE von Apellis Pharmaceuticals Inc ist -40.79%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Apellis Pharmaceuticals Inc
Was macht Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Unternehmen mit roce ähnlich Apellis Pharmaceuticals Inc
- WISeKey International Ltd hat ROCE von -41.00%
- WISeKey International AG hat ROCE von -41.00%
- LiqTech International hat ROCE von -40.94%
- LiqTech International Inc hat ROCE von -40.94%
- NioCorp Developments hat ROCE von -40.90%
- Temas Resources hat ROCE von -40.85%
- Apellis Pharmaceuticals Inc hat ROCE von -40.79%
- Oak Street Health hat ROCE von -40.74%
- Adamas Pharmaceuticals Inc hat ROCE von -40.72%
- Silver Wolf Exploration hat ROCE von -40.67%
- Sherpa II hat ROCE von -40.64%
- The Mandhana Retail Ventures hat ROCE von -40.63%
- Aclaris Therapeutics Inc hat ROCE von -40.61%